Document Detail

Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells.
MedLine Citation:
PMID:  9201249     Owner:  NLM     Status:  MEDLINE    
Previously we have shown that pivaloyloxymethyl butyrate (AN-9), a pro-drug of butyric acid (BA), is a differentiation-inducing agent in a variety of cells. In this report, we demonstrate that AN-9 is a cytostatic but not cytotoxic agent in a myelomonocytic cell line (WEHI); thus, the cells were growth-arrested and differentiated. These late changes in the cells were preceded by changes in the expression of the early regulatory genes, c-myc and c-jun. Although initiation of all these events had already occurred after 1 h exposure to AN-9, the tumorigenicity of these cells tested in Balb/c mice was not affected. A marked reduction in the tumorigenicity of AN-9-treated cells was observed after 4 h of exposure. Exposure of the highly metastatic subclone of Lewis lung carcinoma (3LLD122) to AN-9 resulted in a very pronounced effect on the tumorigenicity of these cells tested in C57BL mice. Unlike WEHI cells, the tumorigenicity of 3LLD122 was almost completely diminished after 1 h of exposure. In both cell types a 10-fold higher concentration of BA did not affect the tumorigenicity of the cells as did AN-9.
A Aviram; A Rephaeli; M Shaklai; A Nudelman; I Ben-Dror; L Maron; E Rabizadeh
Related Documents :
1315439 - Comparison of southern blot analysis with isotopic and nonisotopic in situ hybridizatio...
1723259 - Targeted killing of squamous carcinoma cells by a monoclonal antibody-peplomycin conjug...
6396019 - Kb cells for antinuclear antibody determination: comparison with hep-2 cells and the cr...
17364729 - Biocompatibility of nanocomposites used for artificial conjunctiva: in vivo experiments.
18025279 - Glycosaminoglycans and their synthetic mimetics inhibit rantes-induced migration and in...
6366249 - Abh cell surface isoantigens in invasive bladder carcinoma associated with schistosomia...
9531989 - Enhancement of drug accumulation by andrastin a produced by penicillium sp. fo-3929 in ...
10360369 - Guidelines for the characterization and publication of human malignant hematopoietic ce...
22506669 - Immunohistological diagnosis of plasma cell myeloma based on the cytoplasmic kappa/lamb...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cancer research and clinical oncology     Volume:  123     ISSN:  0171-5216     ISO Abbreviation:  J. Cancer Res. Clin. Oncol.     Publication Date:  1997  
Date Detail:
Created Date:  1997-07-10     Completed Date:  1997-07-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7902060     Medline TA:  J Cancer Res Clin Oncol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  267-71     Citation Subset:  IM    
Institute of Hematology, Rabin Medical Center, Tel Aviv University, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology*
Butyrates / pharmacology*
Carcinoma, Lewis Lung / drug therapy*
Gene Expression Regulation, Neoplastic / drug effects*
Genes, jun / drug effects
Genes, myc / drug effects
Leukemia, Myelomonocytic, Acute / drug therapy*
Mice, Inbred BALB C
Mice, Inbred C57BL
RNA, Neoplasm / drug effects
Tumor Cells, Cultured
Reg. No./Substance:
0/Antineoplastic Agents; 0/Butyrates; 0/RNA, Neoplasm; 122110-53-6/pivalyloxymethyl butyrate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A practical prognostic index for inoperable non-small-cell lung cancer.
Next Document:  Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 ...